Literature DB >> 28577933

Impact of selective reporting of antibiotic susceptibility test results on the appropriateness of antibiotics chosen by French general practitioners in urinary tract infections: a randomised controlled case-vignette study.

Loic Bourdellon1, Nathalie Thilly2, Sébastien Fougnot3, Céline Pulcini4, Sandrine Henard5.   

Abstract

Selective reporting of antibiotic susceptibility test (AST) results is a potential intervention for laboratory-based antibiotic stewardship. The aim of this study was to assess the impact of AST reporting on the appropriateness of antibiotics selected by French general practitioners for urinary tract infections (UTIs). A randomised controlled case-vignette study in a region of northeast France surveyed general practitioners between July and October 2015 on treatment of four clinical cases of community-acquired Escherichia coli UTIs (two cases of complicated cystitis, one of acute pyelonephritis and one male UTI). In Group A, selective reporting of AST results was used for the first two cases and complete reporting for the other two cases; these were reversed in Group B. The overall participation rate was 131/198 (66.2%). Provision of selective AST results significantly increased the rate of adherence to national guidelines for first-line antibiotic treatment in Cases 1, 3 and 4 by 22.4% (55.2% vs. 32.8%, P = 0.01), 67.5% (75.0% vs. 7.5%, P <0.001) and 36.3% (45.3% vs. 9.0%, P <0.001), respectively. The improvement in compliance was not significant for Case 2. Prescriptions of amoxicillin-clavulanic acid, fluoroquinolones and cephalosporins decreased by 25.0% to 45.0%, depending on the clinical vignette. Most (106/131, 81.0%) participants favoured the routine use of selective reporting of AST results. In conclusion, selective reporting of AST results seems to improve antibiotic prescribing practices in primary care, and may be considered a key element of antimicrobial stewardship programmes.
Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Antibiotic prescribing; Antibiotic stewardship; Antibiotic susceptibility testing; Family physicians; Primary care; Questionnaire

Mesh:

Substances:

Year:  2017        PMID: 28577933     DOI: 10.1016/j.ijantimicag.2017.01.040

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  5 in total

1.  Managing ESBL-producing Enterobacteriaceae-related urinary tract infection in primary care: a tool kit for general practitioners.

Authors:  Aurélie Zucconi; Johan Courjon; Christophe Maruéjouls; Fabrice Saintpère; Nicolas Degand; Lilli Pandiani; Christian Pradier; Véronique Mondain
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-28       Impact factor: 3.267

2.  Effects of cascade reporting of susceptibility profiles for Enterobacterales on broad-spectrum antibiotics use and resistance.

Authors:  Laura Heireman; Stien Vandendriessche; Liselotte Coorevits; Franky Buyle; Jan De Waele; Dirk Vogelaers; Bruno Verhasselt; Jerina Boelens
Journal:  Eur J Hosp Pharm       Date:  2022-03

3.  Impact of cascade reporting of antimicrobial susceptibility on fluoroquinolone and meropenem consumption at a Veterans' Affairs medical center.

Authors:  Nicole C Vissichelli; Christine M Orndahl; Jane A Cecil; Emily M Hill; Matthew M Hitchcock; Roy T Sabo; Michael P Stevens; Dan Tassone; Leroy B Vaughan; J Daniel Markley
Journal:  Infect Control Hosp Epidemiol       Date:  2021-04-06       Impact factor: 6.520

4.  Treatment of urinary tract infections in Swiss primary care: quality and determinants of antibiotic prescribing.

Authors:  Andreas Plate; Andreas Kronenberg; Martin Risch; Yolanda Mueller; Stefania Di Gangi; Thomas Rosemann; Oliver Senn
Journal:  BMC Fam Pract       Date:  2020-07-01       Impact factor: 2.497

5.  Impact of selective reporting of antibiotic susceptibility test results in urinary tract infections in the outpatient setting: a protocol for a pragmatic, prospective quasi-experimental trial.

Authors:  Francesca Binda; Sébastien Fougnot; Patrice De Monchy; Anne Fagot-Campagna; Céline Pulcini; Nathalie Thilly
Journal:  BMJ Open       Date:  2019-02-22       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.